tiprankstipranks
Advertisement
Advertisement

Altimmune Sets 2026 Annual Stockholder Meeting Timeline

Story Highlights
  • Altimmune set its 2026 annual shareholder meeting for April 16, 2026, with a March 13 record date.
  • The company tightened governance timelines, setting mid-February deadlines for proposals and proxy-related director nominations.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Altimmune Sets 2026 Annual Stockholder Meeting Timeline

Claim 55% Off TipRanks

Altimmune ( (ALT) ) has issued an announcement.

Altimmune has scheduled its 2026 Annual Meeting of Stockholders for April 16, 2026, shifting the event to the second quarter to align with the standard annual meeting calendar for companies with a December 31 fiscal year-end, and set March 13, 2026 as the record date for determining shareholders entitled to receive notice and vote, with the meeting expected to be held virtually as in prior years. Because this meeting date differs by more than 30 days from the prior year’s September 25, 2025 annual meeting, the company has established new governance timelines, including a February 13, 2026 deadline for shareholder proposals and director nominations under both SEC Rule 14a-8 and its bylaws, and a February 15, 2026 deadline for stockholders intending to solicit proxies for alternative director nominees under universal proxy rules, clarifying the framework for shareholder participation and potential proxy contests.

The most recent analyst rating on (ALT) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.

Spark’s Take on ALT Stock

According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.

The score is held down primarily by severe and persistent unprofitability and negative cash flows. Offsetting this are strong technical momentum and a constructive clinical/regulatory outlook from the earnings call and recent trial updates, though dilution risk from equity financing and overbought technical conditions limit the overall rating.

To see Spark’s full report on ALT stock, click here.

More about Altimmune

Altimmune, Inc. operates in the biopharmaceutical industry, focusing on the development of therapeutics and vaccines, with its corporate headquarters located in Gaithersburg, Maryland, and a typical public-company governance structure that includes an annual meeting of stockholders aligned with a calendar-year fiscal year-end.

Average Trading Volume: 4,957,957

Technical Sentiment Signal: Hold

Current Market Cap: $701.3M

Find detailed analytics on ALT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1